

Answers.com™

oleaginous

Dictionary



o·le·ag·i·nous (ō'lē-ăj'ō-nəs)

adj.

1. Of or relating to oil.
2. Falsely or smugly earnest; unctuous: *oleaginous flattery*. See synonyms at [unctuous](#).

[From Middle English oliaginous and from French oléagineux (from Old French), both from Latin oleāginus, of the olive tree, from olea, olive tree, alteration (influenced by oleum, olive oil) of olīva; see [olive](#).]

oleaginously o'le-ag'i-nous-ly *adv.*
oleaginousness o'le-ag'i-nous-ness *n.*

Thesaurus



oleaginous

adjective

1. Having the qualities of fat: [adipose](#), [fat](#), [fatty](#), [greasy](#), [oily](#), [unctuous](#). See [fat/thin](#).
2. Affectedly and self-servingly earnest: [fulsome](#), [oily](#), [sleek](#), [smarmy](#), [unctuous](#). See [attitude/good attitude/bad attitude/neutral attitude, honest/dishonest](#).

Medical



o·le·ag·i·nous (ō'lē-ăj'ō-nəs)
adj.

Oily; greasy.

Obscure Words



oleaginous

Resembling or having the properties of oil; [unctuous](#)

Devil's Dictionary



A [cynical](#) view of the world by [Ambrose Bierce](#)

oleaginous
adj.

Oily, smooth, sleek.

Disraeli once described the manner of Bishop Wilberforce as "unctuous, oleaginous, saponaceous." And the good prelate was ever afterward known as Soapy Sam. For every man there is something in the vocabulary that would stick to him like a second skin. His enemies have only to find it.



Note: click on a word meaning below to see its connections and related words.

The *adjective* oleaginous has 2 meanings:

Meaning #1: unpleasantly and excessively suave or ingratiating in manner or speech

Synonyms: buttery, fulsome, oily, smarmy, unctuous

Meaning #2: containing an unusual amount of grease or oil

Synonyms: greasy, oily, sebaceous

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Tuesday, March 20, 2007

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L6	L5 and l1	7
<input type="checkbox"/>	L5	pluronic or oil	2043013
<input type="checkbox"/>	L4	L3 and l1	6
<input type="checkbox"/>	L3	oleaginous or cholesterol microsphere	12747
<input type="checkbox"/>	L2	20040180083.pn.	2
<input type="checkbox"/>	L1	olanzapine pamoate	13


END OF SEARCH HISTORY

10613619

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 132539-06-1 REGISTRY
ED Entered STN: 08 Mar 1991
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl) -
(CA INDEX NAME)

OTHER NAMES:

CN Lanzaac
CN LY 170053
CN Olanzapine
CN Zyprexa
MF C17 H20 N4 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHM, DDFU, DRUGU, EMBASE,
IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1918 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1929 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10613619

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 130-85-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy- (9CI) (CA
INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,2'-Dihydroxy-1,1'-dinaphthylmethane-3,3'-dicarboxylic acid
CN 4,4'-Methylenebis[3-hydroxy-2-naphthoic acid]
CN Bis(2-hydroxy-3-carboxy-1-naphthyl)methane
CN Embonic acid
CN KG 122
CN NSC 30188
CN NSC 40132
CN Pamoic acid
DR 122541-93-9, 67232-45-5, 50857-36-8, 108626-78-4, 47620-91-7
MF C23 H16 O6
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS,
CASREACT, CHEMCATS, CHEMLIST, CSCHM, DDFU, DRUGU, EMBASE, IFICDB,
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PS, RTECS*, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

178 REFERENCES IN FILE CA (1907 TO DATE)
18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
178 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Blessing Fubara

10613619

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 221373-18-8 REGISTRY

ED Entered STN: 21 Apr 1999

CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
(1:1), monohydrate (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
, 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (1:1), monohydrate
(9CI)

OTHER NAMES:

CN Olanzapine pamoate

MF C23 H16 O6 . C17 H20 N4 S . H2 O


SR CA

LC STN Files: CA, CAPLUS, IMSPATENTS, PROUSDDR, SYNTHLINE, USPAT2,
USPATFULL

CM 1

CRN 132539-06-1

CMF C17 H20 N4 S




Olanzapine

CM 2

CRN 130-85-8

CMF C23 H16 O6



Blessing Fubara

10613619

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Blessing Fubara

10613619

(FILE 'HOME' ENTERED AT 11:36:41 ON 20 MAR 2007)

FILE 'REGISTRY' ENTERED AT 11:38:41 ON 20 MAR 2007

L1	0 S OLANZAPINE PAMOATE MONOHYDRATE/CN
L2	1 S OLANZAPINE PAMOATE/CN
L3	1 S OLANZAPINE/CN
L4	0 S PAMOATE/CN
L5	0 S PAMIC/CN
L6	0 S PAMIC ACID/CN
L7	0 S PAMOIC/CN
L8	1 S PAMOIC ACID/CN

=>

10613619

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:674014 CAPLUS
DOCUMENT NUMBER: 145:130622
TITLE: Olanzapine pamoate dihydrate
INVENTOR(S): Bush, Julie Kay
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006073886	A1	20060713	WO 2005-US46752	20051222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-641693P P 20050105
AB The present invention relates olanzapine pamoate dihydrate, pharmaceutical compns. thereof and use in treating certain mental disorders, such as schizophrenia.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 USPATFULL on STN
ACCESSION NUMBER: 2006:47448 USPATFULL
TITLE: Aripiprazole, olanzapine and haloperidol pamoate salts
INVENTOR(S): Greco, Kristyn, N. Quincy, MA, UNITED STATES
Wright, James, Lexington, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006040922	A1	20060223
APPLICATION INFO.:	US 2005-252862	A1	20051018 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-635232, filed on 6 Aug 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELMORE PATENT LAW GROUP, PC, 209 MAIN STREET, N. CHELMSFORD, MA, 01863, US		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	578		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or

Blessing Fubara

10613619

extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:123197 CAPLUS
DOCUMENT NUMBER: 142:204626
TITLE: Aripiprazole, olanzapine and haloperidol pamoate salts
INVENTOR(S): Greco, Kristyn; Wright, James
PATENT ASSIGNEE(S): Alkermes Controlled Therapeutics, II, USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005032836	A1	20050210	US 2003-635232	20030806
US 6987111	B2	20060117		
AU 2004264885	A1	20050224	AU 2004-264885	20040729
CA 2529767	A1	20050224	CA 2004-2529767	20040729
WO 2005016261	A2	20050224	WO 2004-US24344	20040729
WO 2005016261	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1651219	A2	20060503	EP 2004-779410	20040729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007501235	T	20070125	JP 2006-522613	20040729
US 2006040922	A1	20060223	US 2005-252862	20051018
PRIORITY APPLN. INFO.:			US 2003-635232	A 20030806
			WO 2004-US24344	W 20040729

AB The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole. Thus, 2.5 mL of a 0.1 M solution of haloperidol in an acidified ethanol was added to 2.5 mL of a 0.1 M solution

10613619

of disodium pamoate in ethanol/water (50/50). The mixture was allowed to sit at room temperature for 1-3 days. The resulting precipitate was filtered off by

suction, washed with ethanol and dried in a vacuum oven at 60°, yielding 240 mg of 1:1 haloperidol pamoate salt.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:127505 USPATFULL

TITLE: 2-methyl-thieno-benzodiazepine formulation

INVENTOR(S): Allen, Douglas J., Indianapolis, IN, UNITED STATES

Dekemper, Kurt D., Franklin, IN, UNITED STATES

Ferguson, Thomas H., Greenfield, IN, UNITED STATES

Garvin, Stuart J., Plainfield, IN, UNITED STATES

Murray, Linda C., Noblesville, IN, UNITED STATES

Brooks, Norman D., Greenfield, IN, UNITED STATES

Bunnell, Charles A., Lafayette, IN, UNITED STATES

Mascarenhas, Snehlata S., Indianapolis, IN, UNITED STATES

Shinkle, Sharon L., Indianapolis, IN, UNITED STATES

Hendriksen, Barry A., Guildford, UNITED KINGDOM

Tupper, David E., Reading, UNITED KINGDOM

Sanchez-Felix, Manuel V., Grayshot, UNITED KINGDOM

NUMBER KIND DATE

PATENT INFORMATION: US 2004097489 A1 20040520

APPLICATION INFO.: US 2003-613619 A1 20030703 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-136887, filed on 1 May 2002, GRANTED, Pat. No. US 6617321 Continuation of Ser. No. US 2000-509757, filed on 29 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US20426, filed on 30 Sep 1998, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 1997-60493P 19970930 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

LINE COUNT: 1719

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

L3 ANSWER 5 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:38169 USPATFULL

TITLE: 2-methyl-thieno-benzodiazepine formulation

INVENTOR(S): Allen, Douglas J., Indianapolis, IN, UNITED STATES

Dekemper, Kurt D., Franklin, IN, UNITED STATES

Ferguson, Thomas H., Greenfield, IN, UNITED STATES

Garvin, Stuart J., Plainsfield, IN, UNITED STATES

Murray, Linda C., Noblesville, IN, UNITED STATES

Blessing Fubara

10613619

Brooks, Norman D., Greenfield, IN, UNITED STATES
Bunnell, Charles A., Lafayette, IN, UNITED STATES
Mascarenhas, Snehlata S., Indianapolis, IN, UNITED STATES
Shinkle, Sharon L., Indianapolis, IN, UNITED STATES
Hendriksen, Barry A., Guildford, UNITED KINGDOM
Tupper, David E., Reading, UNITED KINGDOM
Sanchez-Felix, Manuel V., Grayshott, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027816	A1	20030206
	US 6617321	B2	20030909
APPLICATION INFO.:	US 2002-136887	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-509757, filed on 29 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US20426, filed on 30 Sep 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60493P	19970930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1727	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

L3 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2001:1771 USPATFULL
TITLE: 2-methyl-thieno-benzodiazepine formulation
INVENTOR(S): Bunnell, Charles Arthur, Lafayette, IN, United States
Ferguson, Thomas Harry, Greenfield, IN, United States
Hendriksen, Barry Arnold, Guildford, United Kingdom
Sanchez-Felix, Manuel Vicente, Grayshott, United Kingdom
Tupper, David Edward, Reading, United Kingdom
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6169084	B1	20010102
APPLICATION INFO.:	US 1998-163769		19980930 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60493P	19970930 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Palmberg, Arleen	

Blessing Fubara

10613619

NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:227510 CAPLUS

DOCUMENT NUMBER: 132:256034

TITLE: 2-Methylthienobenzodiazepine formulation

INVENTOR(S): Bunnell, Charles Arthur; Ferguson, Thomas Harry; Hendriksen, Barry Arnold; Sanchez-Felix, Manuel Vicente; Tupper, David Edward

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018408	A1	20000406	WO 1999-US6417	19990324
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6169084	B1	20010102	US 1998-163769	19980930
CA 2344873	A1	20000406	CA 1999-2344873	19990324
AU 9933627	A	20000417	AU 1999-33627	19990324
AU 759751	B2	20030501		
BR 9914156	A	20010626	BR 1999-14156	19990324
EP 1119359	A1	20010801	EP 1999-915009	19990324
EP 1119359	B1	20040526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100885	T2	20010821	TR 2001-200100885	19990324
HU 200103636	A2	20020128	HU 2001-3636	19990324
JP 2002525330	T	20020813	JP 2000-571926	19990324
NZ 510208	A	20030429	NZ 1999-510208	19990324
AT 267602	T	20040615	AT 1999-915009	19990324
PT 1119359	T	20040831	PT 1999-915009	19990324
EP 1468689	A1	20041020	EP 2004-5832	19990324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES 2221376	T3	20041216	ES 1999-915009	19990324
TW 577890	B	20040301	TW 1999-88105028	19990402
ZA 2001002231	A	20020318	ZA 2001-2231	20010316
IN 2001CN00338	A	20050311	IN 2001-CN338	20010326
NO 2001001583	A	20010328	NO 2001-1583	20010328
HR 2001000238	A1	20020430	HR 2001-238	20010329

Blessing Fubara

10613619

HR 2001000238 B1 20060531
HK 1041199 A1 20050318 HK 2002-100774 20020131
PRIORITY APPLN. INFO.: US 1998-163768 A 19980930
US 1998-163769 A 19980930
US 1997-60493P P 19970930
EP 1999-915009 A3 19990324
WO 1999-US6417 W 19990324

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates. Thus, olanzapine was prepared and mixed with cholesterol in methylene chloride. An aqueous solution of PVA was added to the above solution and

the mixture was passed through 100- and 230-mesh sieves, and the particles thus obtained were allowed to dry.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:233762 CAPLUS

DOCUMENT NUMBER: 130:257362

TITLE: Methylthienobenzodiazepine derivative antipsychotic drug formulation.

INVENTOR(S): Allen, Douglas James; Dekemper, Kurt Douglas; Ferguson, Thomas Harry; Garvin, Stuart James; Murray, Linda Cameron; Brooks, Norman Dale; Bunnell, Charles Arthur; Hendriksen, Barry Arnold; Mascarenhas, Snehlata Singh; Shinkle, Sharon Louise; Sanchez-Felix, Manuel Vicente; Tupper, David Edward

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916313	A1	19990408	WO 1998-US20426	19980930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2304568	A1	19990408	CA 1998-2304568	19980930
AU 9895914	A	19990423	AU 1998-95914	19980930
AU 752552	B2	20020919		
EP 1018880	A1	20000719	EP 1998-949632	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9813228	A	20000829	BR 1998-13228	19980930
HU 200004534	A2	20010528	HU 2000-4534	19980930
TR 200000812	T2	20010723	TR 2000-200000812	19980930
JP 2001517685	T	20011009	JP 2000-513467	19980930
NZ 503641	A	20020927	NZ 1998-503641	19980930
MX 200003040	A	20001110	MX 2000-3040	20000328

Blessing Fubara

10613619

NO 2000001631	A	20000530	NO 2000-1631	20000329
HR 2000000181	A1	20001231	HR 2000-181	20000331
HR 2000000181	B1	20060731		
US 2003027816	A1	20030206	US 2002-136887	20020501
US 6617321	B2	20030909		
US 2004097489	A1	20040520	US 2003-613619	20030703
PRIORITY APPLN. INFO.:			US 1997-60493P	P 19970930
			WO 1998-US20426	W 19980930
			US 2000-509757	B1 20000329
			US 2002-136887	A1 20020501

AB The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1.5]benzodiazepine (olanzapine) (preparation given) or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10613619

(FILE 'HOME' ENTERED AT 15:38:49 ON 20 MAR 2007)

FILE 'REGISTRY' ENTERED AT 15:39:17 ON 20 MAR 2007

L1 1 S OLANZAPINE PAMOATE/CN

FILE 'CAPLUS, USPATFULL' ENTERED AT 15:40:35 ON 20 MAR 2007

L2 9 S L1

L3 8 DUP REMOVE L2 (1 DUPLICATE REMOVED)